ITEMS IN AFP WITH KEYWORD:
The Society for Vascular Surgery collaborated with the American Podiatric Medical Association and the Society for Vascular Medicine to create evidence-based guidelines to improve the care of patients with a diabetic foot.
In multiple randomized trials, the long-term use of second- or third-generation sulfonylureas in patients with type 2 diabetes is not associated with more deaths, myocardial infarctions (MIs), or strokes. The included trials tended not to report other safety data.
Painful diabetic neuropathic pain causes patients to experience burning pain, paresthesias, and numbness that progress from the feet and hands to the rest of the body. Although several therapeutic modalities are available for its treatment, many patients do not receive adequate care.
Although most recent practice guidelines have relaxed the blood pressure goals for patients with diabetes, there are still a few holdouts that suggest aggressive treatment. This analysis shows that the ideal range for hypertension control in patients with diabetes is between 140 and 150 mm Hg; highe...
Jun 15, 2016 Issue
Screening for Abnormal Blood Glucose and Type 2 Diabetes Mellitus [Putting Prevention into Practice]
M.A. is a 43-year-old woman with a seven pack-year smoking history. She has no health concerns and has not visited a physician in four years. Her blood pressure and pulse are normal, and her body mass index (BMI) is 27 kg per m2. She does not have a family history of diabetes mellitus but notes that...
May 1, 2016 Issue
Alpha-Lipoic Acid for Treatment of Diabetic Peripheral Neuropathy [FPIN's Help Desk Answers]
Intravenous (IV) ALA can improve neuropathy symptoms when administered for three weeks, but symptom improvement with oral ALA is not clinically significant. There is no evidence evaluating long-term treatment.
In this group of older patients (mean age = 68 years) who do not have diabetes but are at high risk of cardiovascular disease, a more aggressive systolic BP target of 120 mm Hg instead of 140 mm Hg led to benefits (lower all-cause mortality, lower cardiovascular mortality, less heart failure), but a...
In patients with established CV disease and type 2 diabetes, the addition of empagliflozin to standard therapy reduces all-cause mortality and CV mortality. This is notable because empagliflozin is the only drug other than metformin to demonstrate a mortality benefit, albeit for a fairly narrow group of patients.
The American Heart Association (AHA) and American Diabetes Association (ADA) joined together to release statements on preventing CVD in persons with diabetes.
Review key screening recommendations for type 2 diabetes in nonpregnant adults, pregnant women, children, and older persons. Learn which test results are considered diagnostic.